Hemab Therapeutics is a pre-revenue biotech with a 58.5% gap to the analyst target and institutional accumulation, but quality is below the floor, there is no revenue, and the outcome is binary on clinical results.
Thesis pillars
- Pre Revenue Quality Below Floor→Stable
- Analyst Target Upside→Stable
- Institutions Accumulating→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026
Hemab Therapeutics Holdings, In (COAG) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $38.50: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is... Read more
Sell if holding. Engine safety override at $38.50: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.9/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 17d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Hemab Therapeutics Holdings, In
Latest news
- NEWS J.P. Morgan and Rodman & Renshaw Initiate Coverage on Hemab Therapeutics Holdings, Inc. — fiscal.ai Oct 29, 2026 positive
- NEWS JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70 — benzinga Oct 15, 2026 positive
- NEWS Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56 — benzinga Oct 12, 2026 positive
- NEWS Hemab Therapeutics Announces First Healthy Volunteer Dosed In Phase 1 Trial Of HMB-003 For Heavy Menstrual Bleeding; Say — benzinga Sep 17, 2026 positive
- NEWS Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket — benzinga Aug 31, 2026 positive
Generated 2026-10-29T13:34:02Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $38.50: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $35.80. Score 5.9/10, moderate confidence.
Analyst target: $54.52 (+41.6% upside). Prior stop was $35.80. Stop-loss: $35.80.
Quality below floor (2.5 < 4.0).
Hemab Therapeutics Holdings, In trades at a P/E of N/A (forward -15.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
11 analysts cover COAG with a consensus score of 4.3/5. Average price target: $63.
What does Hemab Therapeutics Holdings, In do?Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that...
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.